Jonathan Ledermann MD, FRCP
Checkpoint inhibitors are charging ahead in the race toward immunotherapy in the treatment of patients with ovarian cancer. Although studies are still in their early days, there seems to be emerging promise, said Jonathan Ledermann, MD.
during the 2017 ESGO Congress, Ledermann, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discussed the promise of immunotherapy in ovarian cancer and emphasized the importance of participation in clinical trials.
OncLive: What is the status of immunotherapy in the treatment of patients with ovarian cancer?
To summarize, there are now single-agent studies with 4 of the checkpoint inhibitors that have been tested in ovarian cancer. At the moment, we are still at a very early stage in understanding the data. Only 1 of those [trials] has been published; the others have been presented.
... to read the full story